Practice Management
The California Department of Public Health has issued a warning that clade I mpox may be spreading in the state, “primarily impacting communities of gay and bisexual men,” after 3 cases of this rare, more severe strain of mpox were confirmed. At least 1 case occurred in a person with no recent travel who was recently hospitalized and has been discharged to recover at home, indicating that person-to-person community spread of clade I mpox is …
Read More
In 2023, the American Heart Association (AHA) introduced a staging construct for cardiovascular, kidney, and metabolic (CKM) syndrome. Subsequently, a 2024 JAMA article found among a study population of 10,762 U.S. adults, almost 90% met criteria for CKM syndrome (stage 1 or higher), and 15% met criteria for advanced stages between 2011 and 2020. In a new survey of 4,000 adults, AHA found that only 12% of respondents had heard of CKM, and 68% incorrectly …
Read More
In a randomized clinical trial of 800 adults aged 65 years or older with chronic low back pain, both standard acupuncture and enhanced acupuncture with maintenance sessions significantly improved disability related to back pain compared with usual medical care, as published in JAMA Network Open. At 6 months, the adjusted mean disability score (Roland-Morris Disability Questionnaire) improved by −1.0 for standard acupuncture and −1.5 for enhanced acupuncture vs usual care with benefits sustained at 12 …
Read More
About 40% of patients in the University of Colorado Health system who were prescribed a glucagon-like peptide-1 (GLP-1) receptor agonist over a nearly 4 year time span did not fill the prescription, according to a research letter in JAMA Health Forum. Researchers analyzed 9,848 orders for 6,094 unique patients between January 2018 and September 2022, finding that overall, 5,915 (60.1%) orders were filled within 90-days. Patients with both diabetes and obesity were more likely to …
Read More
Roflumilast 0.05% cream, a new once-daily, steroid-free treatment that can be used anywhere on the body, was approved by the Food and Drug Administration to treat mild to moderate atopic dermatitis in children 2 to 5 years of age. According to the manufacturer’s press release, roflumilast can be used for any duration of time, which can be a benefit because the topical steroids that have been a standard treatment are not appropriate for long-term use. …
Read More
An analysis of 19 randomized placebo-controlled trials with 6,506 participants found the commonly prescribed pain drug tramadol only modestly reduced pain scores for chronic pain—showing improvement of just 0.93 points on a 0–10 numerical scale (97.5% confidence interval [CI], −1.26 to −0.60; p < 0.0001). The effect size fell below a minimal threshold of 1.0 point as defined by the authors. Additionally, serious adverse events were more common with tramadol (odds ratio [OR] 2.13; 97.5% …
Read More
Healthcare workers don’t reliably test for respiratory viruses when they have symptoms, despite their risk for exposure to viruses on the job. From September 2024 to February 2025, 893 healthcare workers in Ireland completed surveys about respiratory symptoms and testing. As reported in Antimicrobial Stewardship & Healthcare Epidemiology, among 321 workers with symptoms, only 202 (63%) participants used self-administered antigen tests for COVID-19. Self-testing had a greater association with female sex, those with a preexisting …
Read More
Prostate cancer rates have increased in recent years, especially in cases with advanced stages, according to the American Cancer Society as published in its CA flagship journal. Incidence grew at 3.0% annually from 2014 through 2021, just after a period of 6.4% annual decreases from 2007 through 2014. Over the past decade, late-stage disease has increased by 2.6% annually in men younger than 55 years, 6.0% annually in men aged 55–69 years, and 6.2% annually …
Read More
The Food and Drug Administration (FDA) has approved oral remibrutinib, a new drug product, as a second-line treatment for chronic spontaneous urticaria (CSU). Remibrutinib has a unique mechanism to block the activity of Bruton’s tyrosine kinase (BTK), stopping a key pathway of the immune response in CSU, according to a manufacturer press release. The condition is thought to be caused by immune dysregulation, and it is believed that once activated, BTK leads to the release …
Read More
A large study in the Journal of the American College of Cardiology found that 99% of those who experience heart attacks and strokes have at least 1 of the 4 biggest risk factors. By tracking health records for more than a decade in more than 9.3 million adults in South Korea and nearly 7,000 adults in the United States, researchers found that virtually all subjects had at least 1 major cardiovascular risk factor beforehand, and …
Read More